The female infertility diagnosis and treatment market involves the diagnosis and treatment of various medical conditions that can lead to infertility in women. Infertility can be caused by a wide range of factors, including hormonal imbalances, ovarian dysfunction, fallopian tube damage, uterine abnormalities, and age-related factors. According to the World Health Organization’s (WHO) report published in April 2023, infertility affects around 17.5% of the adult population, or nearly 1 in every 6 people globally, highlighting the critical requirement to provide access to inexpensive, high-quality reproductive care. Additionally, according to World Bank data, in 2020, the total fertility rate among women was 2.3%, compared to 5.3% in 1963. Hence, the market is witnessing various new treatments and drugs to increase women’s fertility rates.
Browse the full report description of “Global Female Infertility Diagnosis and Treatment Market Size, Share & Trends Analysis Report by Diagnosis (Ovulation Testing, Hysterosalpingography (HSG), Hysteroscopy, Imaging Testing, Ovarian Reserve Testing, Hormonal Level Testing, Genetic Testing, and Others)by Treatment (Drugs, Surgery, Intrauterine Insemination (IUI), Assisted Reproductive Technology (ART)) by End User(Hospitals and Clincis, Homecare, and Pathology and Diagnostic Centers) Forecast 2023-2030” at https://www.omrglobal.com/industry-reports/female-infertility-market-size
The market for female infertility diagnosis and treatment includes diagnostic tests such as ovulation testing, hysterosalpingography, hysteroscopy, ovarian reserve testing, hormonal level testing, genetic testing, and others (laparoscopy and endometrial biopsy). The treatment types on the market include drugs, intrauterine insemination (IUI), surgery, assisted reproductive technology (ART), and others (hormone replacement therapy). Owing to the vast number of diagnosis and treatment options that are available in the market, it is projected to grow at a CAGR of 5.6% over the projected period (2022-2028).
Key Trends in the Female Infertility Diagnosis and Treatment Market
Increasing Use of IVF and IUI
IVF and IUI are the most used ART procedures for female infertility treatment. IVF involves fertilizing an egg with sperm outside of the body and transferring the resulting embryo to the uterus. IUI involves placing sperm directly into the uterus. Both procedures have seen increased use in recent years, with IVF success rates improving due to advances in technology. Examples of companies offering IVF and IUI services include The Fertility Centers of New England and The Reproductive Medicine Group. Additionally, new facilities are also starting to provide IVF services. For instance, in June 2022, Tree Top Hospital requested approval from the Ministry of Health to begin IVF in the Maldives. IUI and IVF are the available therapies for infertility. Currently, IUI therapy is the only accessible technique in the Maldives. As a result, patients must fly abroad to have IVF therapy, which is costly because it is not covered under the Aasandha insurance system. Hence, the hospital is planning to offer IVF services to its patients under the Aasandha insurance scheme.
Focus on Personalized Medicine
Personalized medicine involves tailoring treatment to an individual's unique genetic makeup and medical history. This approach is becoming more common in female infertility diagnosis and treatment, with companies offering personalized treatment plans based on factors such as age, hormonal levels, and genetic testing results. Examples of companies offering personalized infertility treatments include Progyny, Vios Fertility Institute, and Celmatix.
Greater Awareness of Infertility Issues
There is a growing awareness of infertility issues among women, which has led to increased advocacy and support for fertility treatments. Women are also more likely to seek out fertility counselling and support groups to help them navigate the emotional and physical challenges of infertility. There are various support organizations as well. For instance, the National Infertility Association (RESOLVE) is a non-profit organization that works to support and advocate for individuals and couples struggling with infertility. They offer educational resources, support groups, and advocacy initiatives to raise awareness of infertility issues and promote access to fertility treatments.
Emphasis on Patient Experience
Fertility treatments can be emotionally and physically draining, and many patients seek a positive and supportive experience during their journey. As a result, there is a growing emphasis on patient experience in the female infertility diagnosis and treatment market. This includes providing extensive education and support, improving communication between patients and providers, and offering a range of additional services such as acupuncture and massage. Examples of companies focusing on the patient experience include Kindbody and Prelude Fertility.
Expansions and Innovations by Major Market Players
The female infertility diagnosis and treatment market has significant contributors such as Bayer AG, Pfizer, Inc., Church & Dwight Co., Inc., Vitrolife, Genea, Ltd., Ferring B.V., and Millendo Therapeutics, Inc. To maintain their competitiveness in the market, some of these players are diversifying their product portfolios and following various mergers and acquisitions activities. Some of the recent developments by these market players include-
• In March 2023, Hera Fertility, a major supplier of fertility treatments, announced the introduction of a new funding option for infertile couples. The new financing plan has 0% interest rates, making it simpler and more reasonable for couples to follow their aspirations of starting a family.
• In October 2022, Triangle Capital Corporation led an $11 million Series C fundraising round for Global Premier Fertility, an innovative reproductive firm that builds, acquires, and oversees fertility clinics and associated companies. The funding round will assist Global Premier Fertility with acquisitions, new clinic construction with current and future physician partners, and investment in recruiting top fertility experts.
Government Regulations and Campaigns to Support the Market
Government regulations and campaigns play an important role in supporting the female infertility market. Several countries, including Australia, Canada, France, and the UK, have nationalized healthcare systems that cover the cost of fertility treatments such as IVF for eligible patients. For instance, in January 2023, the government of New South Wales, Australia, launched the $80 million Affordable IVF Initiative. Over the course of four years, the project will aid around 12,000 women with ART fertility procedures. Women who meet the requirements are now able to receive a cash rebate of $2,000 for IVF and ART treatments. They can do this by accessing their MyService NSW account online or by visiting a government service center.
Governments also launch fertility awareness campaigns to educate the public about fertility issues and encourage women to seek out fertility testing and treatment. For instance, the UK's National Health Service launched a campaign in 2019 to raise awareness of infertility issues and encourage women to seek out fertility testing.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/female-infertility-market-size